US Stock MarketDetailed Quotes
HIMS Hims & Hers Health
- 23.850
- +0.430+1.84%
Trading Nov 7 10:00 ET
5.21BMarket Cap54.20P/E (TTM)
24.240High23.280Low2.32MVolume23.410Open23.420Pre Close55.36MTurnover1.24%Turnover RatioLossP/E (Static)218.48MShares25.74052wk High11.84P/B4.47BFloat Cap6.67552wk Low--Dividend TTM187.48MShs Float25.740Historical High--Div YieldTTM4.10%Amplitude2.720Historical Low23.876Avg Price1Lot Size
Hims & Hers Health Stock Forum
Sign in to post a comment
1
will rich enough tdy ？
6
1
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Hims & Hers Health (HIMS.US)$ great buy
1
Nice move up on earnings. Watch for the GAP to be tested tomorrow.
Larger Image: tradingview.com...
$Hims & Hers Health (HIMS.US)$
Larger Image: tradingview.com...
$Hims & Hers Health (HIMS.US)$
3
$Hims & Hers Health (HIMS.US)$ On conference call Hims & Hers Health Says It Plans to Bring Liraglutide the First Generic GLP-1 in the Market to the Platform in 2025?
2
1
$Hims & Hers Health (HIMS.US)$ & Hers Health, Inc. Reports Third Quarter 2024 Financial Results
Revenue of $401.6 million, up 77% year-over-year in Q3 2024
Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024
Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024
Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million
Revenue of $401.6 million, up 77% year-over-year in Q3 2024
Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024
Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024
Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
10351974 : Yup